drugset / Trial / NCT01367236

Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa

NCT01367236

Phase 4 Completed 60 enrolled Imperial College London Pfizer · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare two different combination anti-HIV therapies over 48 weeks and to assess if differences in improvement in the function of the brain are observed over this period. The study will compare anti-HIV therapy combinations which are currently in use. The patients will not have had any previous treatment for their HIV infection.

Timeline

Start
2013-01
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified 600 mg
Subject Atazanavir Other / unclassified 300 mg
Subject Darunavir Small molecule 800 mg
Subject Lamivudine Other / unclassified 300 mg
Subject Maraviroc Other / unclassified 150 mg
Subject Tenofovir Small molecule 245 mg
Subject emtricitabine Other / unclassified 200 mg
Background Ritonavir Other / unclassified 100 mg